Long-acting cabotegravir/rilpivirine, lenacapavir, and ibalizumab use among persons with HIV-1 viremia at a Ryan White-funded clinic in the urban U.S. South

利比韦林 病毒血症 医学 病毒载量 人类免疫缺陷病毒(HIV) 抗逆转录病毒疗法 内科学 病毒学
作者
Jonathan Colasanti,Amalia Aldredge,Larisa Niles-Carnes,Eudiah Ochieng,Priyasha Pareek,Victoria Robinson,Erica Anderson,Mary Carmen Amigo Castañeda,Hilary Spralling,Bradley L. Smith,Jeri Sumitani,Eric Paul Leue,Caitlin A. Moran,Meredith Lora,Wendy S. Armstrong,Lauren F. Collins
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
标识
DOI:10.1093/cid/ciaf425
摘要

Abstract Background People with HIV (PWH) with viremia despite oral antiretroviral therapy (ART) can achieve viral suppression (VS) using long-acting (LA)-ART. Scaling this approach has lagged, especially in highest HIV burden areas. Methods We performed a retrospective review of PWH who initiated LA-ART (cabotegravir/rilpivirine [CAB/RPV] ± lenacapavir [LEN] ± ibalizumab [IBA]) with viremia (≥50 c/mL) at a Ryan White-funded program in the urban South between 4/14/2021–8/31/2024. Among PWH who received ≥3 LA-CAB/RPV injections through end of follow-up (12/31/2024), achieving VS (<50 c/mL) was assessed. Results 81 PWH with viremia initiated LA-ART. 93% identified as Black, 40% were cis/trans-women, median (Q1-Q3) age was 38 (30-49) years and income $25K/yr ($20-33K/yr). Median (Q1-Q3) years since HIV diagnosis was 15.5 (8.8-20.5) and 46% had prior opportunistic conditions. At LA-ART initiation (56 CAB/RPV; 22 CAB±RPV+LEN; 3 CAB±RPV+LEN+IBA), median (Q1-Q3) viral load was 4.0 (2.9-4.8) log10 and CD4+ 186 (62-420) cells/μL. Of 79 PWH who remained engaged, 73 (92%) achieved VS after a median (Q1-Q3) of one (1-2) injection, with CD4 rise to 353 (187-501) cells/μL. Otherwise, two had virologic failure with drug resistance; four had persistent viremia without resistance (>200 c/mL [n=2]; 50-200 c/mL [n=2]). Of 645 LA-CAB/RPV injections (500 Q4wk; 145 Q8wk), 635 (98%) were administered on-time; all LEN (43/43) and IBA (37/37) administrations occurred on-time. Conclusions In the largest Southern US cohort of PWH with viremia initiating LA-ART, 92% achieved VS despite significant barriers to care and disease burden, underscoring LA-ART as a tool to help achieve Ending the HIV Epidemic goals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bkagyin应助拉扣采纳,获得10
1秒前
大白发布了新的文献求助10
1秒前
大力一德完成签到,获得积分10
1秒前
1秒前
小满应助Hyria采纳,获得10
2秒前
nyfz2002完成签到,获得积分10
2秒前
科研通AI6.3应助TZJ采纳,获得30
2秒前
xxx完成签到 ,获得积分10
3秒前
3秒前
大意的楼房完成签到,获得积分10
3秒前
龙仔完成签到 ,获得积分10
3秒前
xj305完成签到,获得积分10
4秒前
4秒前
李凭中国弹箜篌完成签到,获得积分10
4秒前
高兴的羊完成签到,获得积分10
4秒前
科研通AI6.4应助CJL采纳,获得10
4秒前
Bake完成签到 ,获得积分10
4秒前
5秒前
jingutaimi完成签到,获得积分10
5秒前
宇宙尽头完成签到,获得积分10
6秒前
6秒前
时尚若雁完成签到,获得积分10
6秒前
杨三完成签到 ,获得积分10
6秒前
7秒前
7秒前
冷静的访天完成签到 ,获得积分0
8秒前
8秒前
伊里七完成签到 ,获得积分10
8秒前
路先生发布了新的文献求助10
8秒前
张张完成签到,获得积分10
9秒前
科研通AI2S应助cjk采纳,获得10
9秒前
酸色黑樱桃完成签到,获得积分10
9秒前
小高发布了新的文献求助10
9秒前
舒适忆曼完成签到,获得积分10
10秒前
土豆丝发布了新的文献求助10
10秒前
幽默的尔蓝完成签到,获得积分10
10秒前
yyyyyge完成签到,获得积分10
10秒前
佳期如梦完成签到 ,获得积分10
11秒前
duanzou完成签到,获得积分10
11秒前
CC完成签到,获得积分10
12秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7298467
求助须知:如何正确求助?哪些是违规求助? 8916902
关于积分的说明 18880297
捐赠科研通 6963561
什么是DOI,文献DOI怎么找? 3210666
关于科研通互助平台的介绍 2379981
邀请新用户注册赠送积分活动 2187150